Urticaria is a common and heterogeneous inflammatory skin disorder classified as either acute urticaria (≤ 6 weeks) or chronic urticaria (> 6 weeks). This program provides evidence-based guidance on the initial assessment and management of urticaria and angioedema, focusing on first-line treatment in adults with second-generation over-the-counter (OTC) H1-antihistamines.
This program has received an educational grant or in-kind support from Sanofi.